治疗方案可能会影响肝硬化的肠道微生物组衍生特征。

Treatment regimens may compromise gut-microbiome-derived signatures for liver cirrhosis.

机构信息

Key Laboratory of Molecular Biophysics of the Ministry of Education, Hubei Key Laboratory of Bioinformatics and Molecular Imaging, Center for Artificial Intelligence Biology, Department of Bioinformatics and Systems Biology, College of Life Science and Technology, Huazhong University of Science and Technology, 430074 Wuhan, Hubei, China.

Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, 200433 Shanghai, China; Key Laboratory of Computational Neuroscience and Brain-Inspired Intelligence, Ministry of Education, Shanghai 200433, China; Research Institute of Intelligent Complex System, Fudan University, Shanghai 200433, China.

出版信息

Cell Metab. 2021 Mar 2;33(3):455-456. doi: 10.1016/j.cmet.2021.02.012.

DOI:10.1016/j.cmet.2021.02.012

PMID:33657385

Abstract

Many of the gut-microbiome-derived signatures for liver cirrhosis, especially the important ones, were likely under the influence of proton pump inhibitors (PPIs). Wu et al. suggest that drug usage is a confounding factor in metagenomics analysis that should be controlled for.

摘要

许多源自肠道微生物组的肝硬化特征，尤其是重要的那些，可能受到质子泵抑制剂（PPIs）的影响。Wu 等人建议，药物使用是宏基因组分析中的一个混杂因素，应该加以控制。